Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PLEC | Q15149 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27111060 | 0.85 | PRKCI (0.73) | PRKCIMAPTCREBBPNPC1AKR1C3 | |
| SCHEMBL1067119 | 0.85 | PRKCI (0.73) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL1270367 | 0.85 | PRKCI (0.73) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL18833886 | 0.83 | PRKCI (0.71) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL2248152 | 0.83 | PRKCI (0.71) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL18691959 | 0.83 | PRKCI (0.71) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL7105521 | 0.83 | PRKCI (0.71) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL20630760 | 0.82 | PRKCI (0.69) | PRKCIMAPTNPC1AKR1C3AKR1C2 | |
| SCHEMBL542066 | 0.81 | PRKCI (0.69) | PRKCIMAPTKDM4EGAAALDH1A1 | |
| SCHEMBL18229474 | 0.81 | PRKCI (0.69) | PRKCIMAPTKDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-8759535-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (US) | 2013-08-22 | — | — | US | disclosed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | PRKCI 1796/4885MAPT 2385/4885KDM4E 2451/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | PRKCI 1796/4885MAPT 2385/4885KDM4E 2451/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | PRKCI 1796/4885MAPT 2385/4885KDM4E 2451/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | PRKCI 1509/4885MAPT 1693/4885KDM4E 2243/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | PRKCI 914/4885MAPT 4519/4885KDM4E 1931/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | PRKCI 1966/4885MAPT 2557/4885KDM4E 2332/4885 |
| US-20130217669-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | PRKCI 914/4885MAPT 4519/4885KDM4E 1931/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | PRKCI 1796/4885MAPT 2385/4885KDM4E 2451/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | PRKCI 1190/4885MAPT 2411/4885KDM4E 1595/4885 |
| US-20190194181-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, UACA | PRKCI 1476/4885MAPT 1261/4885KDM4E 2862/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | PRKCI 914/4885MAPT 4519/4885KDM4E 1931/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | PRKCI 1190/4885MAPT 2411/4885KDM4E 1595/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | PRKCI 566/4885MAPT 3515/4885KDM4E 125/4885 |
| US-10570126-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | HMOX2, HMOX1, UACA | PRKCI 1476/4885MAPT 1261/4885KDM4E 2862/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | PRKCI 1796/4885MAPT 2385/4885KDM4E 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.